ECM
BMRN icon

Endurant Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Endurant Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-93,600
Closed -$8.11M – 47
2023
Q2 		$8.11M Buy
+93,600
New +$8.81M 7.08% 2

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Endurant Capital Management's BMRN Position: Q1 2024 in Review

Endurant Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 4,650 shares — an estimated $448K sold.

Endurant Capital Management first reported a position in BMRN in Q1 2017 and held it in 11 quarters. The position peaked at $24.9M in Q1 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Endurant Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Endurant Capital Management sold 4,650 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $448K.
  • Endurant Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 11 quarters.
  • Endurant Capital Management's BioMarin Pharmaceuticals position peaked at $24.9M in Q1 2023.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Endurant Capital Management's 13F filing for Q1 2024.